The expression of CLPTM1L was observed to be elevated in lung adenocarcinoma and pancreatic cancer tissues compared to adjacent normal tissues, and poor clinical outcomes were associated with high CLPTM1L expression in patients with pancreatic and lung cancer [30,31]. Here, CLPTM1L is linked to pancreatic neoplasm.